A single and multiple ascending dose study to evaluate the safety and pharmacokinetics of oral PU AD, an epichaperome inhibitor to treat Alzheimer's disease
Breakdown of regulatory pathways designed to prevent aggregation and accumulation of disease associated proteins contributes to or causes Alzheimer's Disease (AD) Under these conditions epichaperomes form and take control of pathological pathways. PU AD is a small molecule, orally bioavailable inhibitor specific to epichaperomes with little or no effect on normal cells, and has shown dramatic beneficial effects in animal models of AD. We describe the first in man trial of PU AD.